Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Non-Current Deferred Tax Liability of $2.4 million for Q1 2026, little changed year-over-year from $2.4 million in Q1 2025, and little changed quarter-over-quarter from $2.4 million in Q4 2025.
Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (changed 0.0% YoY), while the FY2025 annual figure was $2.4 million, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $2.4 million, roughly flat from $2.4 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $7.4 million in Q1 2022, with the low at $2.4 million in Q4 2024.
- The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2023), against an average of $4.3 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then plunged 55.82% in 2023.
- Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then plunged by 55.66% to $3.1 million in 2023, then fell by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
- Business Quant data shows RVMD's Non-Current Deferred Tax Liability at $2.4 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |